Autoimmune thyroiditis Part 3 - Kent Holtorf, MD (2021 Conference) (LDN, low dose naltrexone)

This is Part 3 of Dr. Holtorf’s 3-part series on autoimmune thyroiditis as a core cause of hypothalamic pituitary dysfunction, mitochondrial dysfunction, obesity and systemic illness. This last segment will bring it all together and give practical ways to use this information. 

Autoimmune thyroiditis Part 2 - Kent Holtorf, MD (2021 Conference) (LDN, low dose naltrexone)

This is Part 2 of Dr. Holtorf’s 3-part series on autoimmune thyroiditis as a core cause of hypothalamic pituitary dysfunction, mitochondrial dysfunction, obesity and systemic illness

Autoimmune thyroiditis Part 1 - Kent Holtorf, MD (2021 Conference) (LDN, low dose naltrexone)

Lyme Disease - Darin Ingels, ND (2021 Conference) (LDN, low dose naltrexone)

SIBO - Leonard Weinstock, MD (2021 Conference) (LDN, low dose naltrexone)

Opiate Receptor Drugs – To Cycle or Not to Cycle Dosing? - Paul Anderson, NMD (2021 Conference) (LDN, low dose naltrexone)

History, Pharmacology and Mechanism - Stephen Dickson, BSC (hons) MRPharmS (2021 Conference) (LDN, low dose naltrexone)

LDN Research Trust 2021 Conference - Friday Morning

Samyadev Datta, MD - Pharmacology of Low dose Naltrexone in Chronic Pain Management (2019 Conference) (LDN, low dose naltrexone)

Samyadev Datta, MD discusses LDN and ultra-low dose naltrexone (ULDN) to treat chronic pain and inflammatory/autoimmune conditions. He presents on the history and pharmacology of naltrexone, forms in which LDN can be prepared. Several case studies on pain are presented

Kent Holtorf, MD - LDN should be considered a first-line therapy for CFS/FM (2019 Conference) (LDN, low dose naltrexone)

Kent Holtorf, MD - Causes of Hashimoto's (2019 Conference) (LDN, low dose naltrexone)

Kent Holtorf, MD discusses Hasimoto’s thyroiditis at the LDN 2019 Conference. He discusses the mechanisms of thyroid dysfunction, causes and evaluation of Hashimoto’s thyroiditis, Hashimoto’s in obesity, and treatments of Hasimoto's